PARP7 as a new target for activating anti-tumor immunity in cancer
Recent Publication
Some cancer cells have clever tricks to escape the immune system - one of them is called PARP7. This enzyme helps tumors to suppress certain immune signals or specifically break down important proteins. As a result, the body's own defenses are often thwarted. This is precisely where new research results come in: If you inhibit PARP7, you could wake up the immune cells again and make the tumor vulnerable to attack. A research team, including Prof. Dr. Piero Fossati MD and Prof. DDr. Klaus Podar, has now summarized exactly how PARP7 works and why it could be an exciting target for new cancer therapies.
Popova, K., Benedum, J., Engl, M., Lütgendorf-Caucig, C., Fossati, P., Widder, J., Podar, K., & Slade, D. (2025). PARP7 as a new target for activating anti-tumor immunity in cancer. EMBO Molecular Medicine, Article 108176. Advance online publication. https://doi.org/10.1038/s44321-025-00214-6
Univ.-Prof. Dr. Piero Fossati MD
Head of
Department of Radiation Oncology with an emphasis on Particle Therapy
OA Univ.-Prof. Mag. DDr. Klaus Podar
Head of
Department of Molecular Oncology and Hematology, Division of Internal Medicine 2 (University Hospital Krems)